ARGX•argenx will acquire the remaining shares in Unnatural Products in a deal valued at up to approximately $1.15 billion, including $550 million upfront and up to $595 million in development and regulatory milestone payments.
argenx will pay $550 million upfront from cash on hand, with up to $595 million contingent on development and regulatory milestones. The acquisition adds macrocyclic peptide discovery capabilities to support development of oral and long-acting treatments for serious immune-mediated diseases.
Unnatural Products will retain its team and leadership in Santa Cruz, California, which will become argenx’s peptide discovery hub. Closing is expected by the end of 2026, subject to customary conditions.
